FDA Drops Sham Control for Rare-Disease Gene Therapy (CLPT, QURE)

Between 29 July and 20 August 2026, uniQure (QURE), ClearPoint Neuro (CLPT), Taysha Gene Therapies (TSHA) and BioCardia (BCDA) each told investors on an earnings call — and Herantis Pharma (HRTIS) said in its own press releases — that the FDA has relaxed the control-arm requirement for rare-disease gene therapy [1][2][4][5][6]. The same disclosures point at the two things that remain unsettled: the physical route that puts a drug into the organ, and a functional instrument the agency will accept as a measure of effect.

---

The sham-surgery control the FDA used to demand, and what replaced it

Gene therapy often depends on a surgical procedure that delivers the drug straight into the brain or the heart. To win approval, a sponsor also had to run a randomized sham-surgery trial: one group gets the real procedure and the drug, the other is opened up and given nothing, so that any improvement from expectation alone can be ruled out. Rare-disease populations are small to begin with, and the share willing to accept a sham operation is smaller still, which is why these trials are so hard to complete.

ClearPoint Neuro sells the navigation equipment and single-use cannulas used in those procedures and charges per case. In March 2026 it removed the entire commercial launch revenue for two partner products from its full-year forecast, because the FDA was then demanding the more rigorous trials [3]. By late July the posture had changed. The agency told uniQure that three years of early-phase data would be acceptable as the primary basis of a marketing application, that a sham control is no longer required, and that a standard-of-care-controlled confirmatory study with total functional capacity at 36 months should take its place [1]. What moved is the review standard rather than one product's result, so every sponsor on the same path now has to work out which piece it is still missing.

---

Where the saved money went: instrument development and per-case delivery

ClearPoint cut its 2026 revenue guidance to $48-52 million and attributed the change to redirecting spend away from conventional sales expansion and toward clinical support for commercial drug delivery, global regulatory work and capital equipment. Management expects 10 to 15 trials using ClearPoint technology to be enrolling patients over the next 18 months, and disclosed that a typical procedure generates $12,000-$15,000, with complex cases such as uniQure's running $15,000-$25,000 [2].

Taysha's books run the other way. The company said it took 18 months from concept to locking down its own functional instrument with the FDA, and that it ran a separate study in an untreated population along the way as a baseline; R&D rose to $38.6 million in Q2 2026 from $20.1 million a year earlier [4]. Its stated reason for choosing that endpoint had nothing to do with clearing the agency: the two endpoints already approved in the indication would not, in management's view, have bought a price from payers. Taken together, the two disclosures show that the concession did not lower total spending. It moved it from the control arm to delivery and measurement.

---

Pricing power moves to the operating room and the endpoint vendor

With the control arm no longer the gate, the companies that hold the route into the organ and the tools that measure the effect hold the pricing power in this chain. In the brain the route is already cleared and occupied: ClearPoint charges per case and has disclosed that it can step its price up across bench testing, clinical trials and commercial launch, and in some cases collect a royalty on the drug itself [2]. In the heart the route does not exist. BioCardia says no other catheter has ever been approved for this route of administration and that the gap holds back development across the field; the FDA has acknowledged two clearance pathways for its catheter, and a standalone classification would let later entrants cite it as a predicate device [5].

On the measurement side the consequence is smaller trials. Herantis is running a Phase 2a in roughly 100 newly diagnosed patients over six months with a smartphone-derived Digital Motor Score as the primary endpoint, a design the FDA considered appropriate [6]; the trial Biogen and Denali ran in the same disease on a clinician-administered scale enrolled 648 adults for 48 to 144 weeks [7]. The boundary matters here. PTC Therapeutics and Novartis are still enrolling a Phase 3 of about 770 patients in the very indication where the sham control was dropped, and only plan to discuss accelerated approval with the FDA in the second half of 2026 [8], so this is being granted case by case. What to watch next is whether ClearPoint really does see 10 to 15 trials enrolling over 18 months, and whether BioCardia's standalone clearance path goes through.

---

Companies exposed to this change

• Neurogene (NGNE): Its Rett syndrome gene therapy is dosed by a one-time injection procedure into the brain, and its registrational trial is single-arm and open-label — the design this shift in review standard makes viable — but the company has not disclosed anything on the change itself.
• MeiraGTx (MGTX): Its Parkinson's program is injected directly into a specific structure inside the brain, and its completed Phase 2 randomized 45 patients 1:1 against bilateral sham surgery, so it already paid the cost that has now been dropped. It has made no direct disclosure about the new standard.
• NeuroOne Medical Technologies (NMTC): The other listed company building a route into the brain, facing the same rule — a delivery device is hard to clear on its own when no therapy is approved for that route. It says its robot-assisted platform is on track to be ready for investigational human studies by the end of September 2026.

---

Sources

[1] Drillr · uniQure (QURE) · 2026-07-29 · Q2 FY2026 earnings call

"At this meeting, the FDA communicated that our three-year Phase I-II data would be acceptable as the primary basis of a BLA for the accelerated approval of AMT130. The FDA also requested that we align on the design of the confirmatory trial to support accelerated approval prior to BLA submission. We're working with the FDA to finalize the design of the confirmatory study. However, the critical point is that the FDA agreed that a randomized study using sham control is no longer required. The agency recommended instead that we run a randomized standard of care controlled study with total functional capacity at 36 months as the primary endpoint."

[2] Drillr · ClearPoint Neuro (CLPT) · 2026-08-03 · Q2 FY2026 earnings call

[3] Drillr · ClearPoint Neuro (CLPT) · 2026-03-17 · Q4 FY2025 earnings call

[4] Drillr · Taysha Gene Therapies (TSHA) · 2026-08-11 · Q2 FY2026 earnings call

[5] Drillr · BioCardia (BCDA) · 2026-08-12 · Q2 FY2026 earnings call

[6] BioSpace · Herantis Pharma (HRTIS) · 2026-06-02 · company press release · https://www.biospace.com/press-releases/herantis-reports-positive-fda-feedback-and-finalizes-phase-2a-study-design-for-her-096

[7] AllSci · Denali Therapeutics (DNLI), BIIB122 Phase IIb failure · 2026-05-22 · news report · https://allsci.com/news/clinical-trials/biogen-and-denalis-pull-plug-on-lrrk2-inhibitor-after-phase-ii-failure-in-early-parkinsons/

[8] Drillr · PTC Therapeutics (PTCT) · 2026-07-30 · Q2 FY2026 earnings call

This is only meant to surface industry changes and companies you may have overlooked - it is not a stock recommendation.